SCHEMBL4386339

SCHEMBL4386339

CCOC(=O)c1cc2cc(OC)cc(Cl)c2[nH]1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 6/20 0.60
RAB9A P51151 5/20 0.60
KDM4E B2RXH2 5/20 0.60
ALDH1A1 P00352 5/20 0.60
NPC1 O15118 4/20 0.60
LMNA P02545 3/20 0.60
L3MBTL1 Q9Y468 2/20 0.60
HTT P42858 1/20 0.60
CDK1 P06493 1/20 0.52
CCNB1 P14635 1/20 0.52
ALOX15 P16050 1/20 0.51
MAPT P10636 4/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
GLA P06280 1/20 0.49
GAA P10253 1/20 0.49
ATM Q13315 1/20 0.49
HSD17B10 Q99714 1/20 0.47
HRH3 Q9Y5N1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15563825 0.85 HPGD (0.61) HPGDRAB9AKDM4EALDH1A1NPC1
SCHEMBL4046142 0.85 RAB9A (0.57) HPGDRAB9AKDM4EALDH1A1NPC1
SCHEMBL4396474 0.85 ALOX15 (0.58) HPGDRAB9AKDM4EALDH1A1NPC1
SCHEMBL30457751 0.85 ALOX15 (0.58) HPGDRAB9AKDM4EALDH1A1NPC1
SCHEMBL31440910 0.84 HPGD (0.60) HPGDRAB9AKDM4EALDH1A1NPC1
SCHEMBL1653889 0.84 HPGD (0.60) HPGDRAB9AKDM4EALDH1A1NPC1
SCHEMBL25748610 0.84 HPGD (0.60) HPGDRAB9AKDM4EALDH1A1NPC1
SCHEMBL3106434 0.83 CDK1 (0.54) HPGDRAB9AKDM4EALDH1A1NPC1
SCHEMBL4373098 0.83 CDK1 (0.54) HPGDRAB9AKDM4EALDH1A1NPC1
SCHEMBL12501328 0.82 CDK1 (0.53) HPGDRAB9AKDM4EALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492560-B2 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2013-07-23 US disclosed
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors STOKES ELAINE S E (GB) 2012-08-02 US disclosed
EP-2050744-A1 Quinazoline derivatives as angiogenesis inhibitors AstraZeneca AB (SE) 2009-04-22 EP disclosed
US-7074800-B1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2006-07-11 US disclosed
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB 2006-01-05 US disclosed
EP-1553097-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE AstraZeneca AB (SE) 2005-07-13 EP disclosed
EP-1154774-B1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2005-06-22 EP disclosed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 EP disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors VEGFA, FLT1, KDR HPGD 348/4885RAB9A 225/4885KDM4E 2055/4885
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors FLT4, NOS3, FLT1 HPGD 1830/4885RAB9A 1776/4885KDM4E 1506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.